Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
www.ncbi.nlm.nih.gov/pmc/articles/PMC3553558/
Aug 28, 2020
1
EAU 2020: Perioperative Therapy for Urothelial Cancer: Should We Sequence All Urothelial Cancer Patients?
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123221-eau-2020-perioperative-therapy-for-urothelial-cancer-should-we-sequence-all-urothelial-cancer-patients.html
Aug 1, 2020
10
EAU 2020: Frailty and Cognitive Assessment in Patients Diagnosed with Muscle-Invasive Bladder Cancer
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123173-eau-2020-frailty-and-cognitive-assessment-in-patients-diagnosed-with-muscle-invasive-bladder-cancer.html
Aug 1, 2020
6
EAU 2020: Different Bladder Cancer Genotypes: New Treatment Options
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123177-eau-2020-different-bladder-cancer-genotypes-new-treatment-options.html
Jul 29, 2020
1
EAU 2020: Perioperative Therapy for Urothelial Cancer: Should We Sequence All Urothelial Cancer Patients?
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123221-eau-2020-perioperative-therapy-for-urothelial-cancer-should-we-sequence-all-urothelial-cancer-patients.html
Jul 29, 2020
7
EAU 2020: Recurrence Risk in Patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial ‘NIMBUS’ Stratified for EORTC and CUETO Risk Categories. A contemporary Trend to Less Recurrences?
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123165-eau-2020-recurrence-risk-in-patients-with-high-grade-non-muscle-invasive-bladder-carcinoma-in-the-randomised-phase-iii-clinical-trial-nimbus-stratified-for-eortc-and-cueto-risk-categories-a-contemporary-trend-to-less-recurrences.html
Jul 27, 2020
2
EAU 2020: Early Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancer: A Standard
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123162-eau-2020-early-cystectomy-in-high-risk-non-muscle-invasive-bladder-cancer-a-standard.html
Jul 22, 2020
17
PARP Inhibitors in Prostate Cancer
www.urotoday.com/library-resources/advanced-prostate-cancer/122683-parp-inhibitors-in-prostate-cancer.html
Jul 5, 2020
2
ESMO 2019: Homogenizing Genomic Reports: What Clinicians Need to Know
www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-prostate-cancer/115340-esmo-2019-homogenizing-genomic-reports-what-clinicians-need-to-know.html
Apr 11, 2020
1
EAU 2019: Rare Histological Variants of Prostate Adenocarcinoma: A National Cancer Database (NCDB) Analysis
www.urotoday.com/conference-highlights/eau-annual-congress-2019/eau-2019-prostate-cancer/110924-eau-2019-rare-histological-variants-of-prostate-adenocarcinoma-pca-a-national-cancer-database-ncdb-analysis.html
Apr 11, 2020
3
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/118197-transcriptomic-heterogeneity-of-androgen-receptor-activity-defines-a-de-novo-low-ar-active-subclass-in-treatment-naive-primary-prostate-cancer.html
Apr 11, 2020
2
Primary Tumors Can Tell Us More If We Ask Them To
www.urotoday.com/center-of-excellence/mcrpc-treatment/from-the-editor/118198-primary-tumors-can-tell-us-more-if-we-ask-them-to.html
Apr 11, 2020
11
Response prediction of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/116092-response-prediction-of-177lu-psma-617-rlt-using-psa-chromogranin-a-and-ldh.html
Apr 11, 2020
4
Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/119652-immunohistochemistry-based-assessment-of-androgen-receptor-status-and-the-ar-null-phenotype-in-metastatic-castrate-resistant-prostate-cancer.html
Apr 11, 2020
4
Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/110806-targeting-androgen-receptor-independent-pathways-in-therapy-resistant-prostate-cancer.html
Apr 11, 2020
1
The pitfall of the small cell prostate carcinoma variant resulting in a false-negative bone scan and choline PET/CT study in a case of prostate cancer, "Beyond the Abstract," by Ammad Al Tamimi MD, FRCR
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/71117-the-pitfall-of-the-small-cell-prostate-carcinoma-variant-resulting-in-a-false-negative-bone-scan-and-choline-pet-ct-study-in-a-case-of-prostate-cancer-beyond-the-abstract-by-ammad-al-tamimi-md-frcr.html
Apr 11, 2020
6
The role of lineage plasticity in prostate cancer therapy resistance.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/114430-the-role-of-lineage-plasticity-in-prostate-cancer-therapy-resistance.html
Apr 11, 2020
5
Neuroendocrine Carcinomas of the Genitourinary Tract – Treatment Options Are Desperately Needed… Even During the COVID-19 Pandemic
www.urotoday.com/clinical-trials/from-the-editor/120311-neuroendocrine-carcinomas-of-the-genitourinary-tract-treatment-options-are-desperately-needed-even-during-the-covid-19-pandemic.html
Apr 11, 2020
1
Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/109736-neuroendocrine-differentiation-markers-guide-treatment-sequence-selection-in-metastatic-castration-resistant-prostate-cancer.html
Apr 11, 2020
3
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/114548-parp-inhibition-suppresses-gr-mycn-cdk5-rb1-e2f1-signaling-and-neuroendocrine-differentiation-in-castration-resistant-prostate-cancer.html
Apr 11, 2020
1
Whole Genome and Transcriptional Analysis of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Demonstrates Intra-Class Heterogeneity.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/111366-whole-genome-and-transcriptional-analysis-of-treatment-emergent-small-cell-neuroendocrine-prostate-cancer-demonstrates-intra-class-heterogeneity.html
Apr 11, 2020
3
Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/108923-serum-neuroendocrine-markers-predict-therapy-outcome-of-patients-with-metastatic-castration-resistant-prostate-cancer-a-meta-analysis.html
Apr 11, 2020
2
Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/96102-contemporary-incidence-and-cancer-control-outcomes-of-primary-neuroendocrine-prostate-cancer-a-seer-database-analysis.html
Apr 11, 2020
3
The many faces of neuroendocrine differentiation in prostate cancer progression - Abstract
www.urotoday.com/recent-abstracts/urologic-oncology/investigative-urology/71847-the-many-faces-of-neuroendocrine-differentiation-in-prostate-cancer-progression-abstract.html
Apr 11, 2020
1
Systems Medicine approaches to improving understanding, treatment, and clinical management of Neuroendocrine Prostate Cancer
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/88807-systems-medicine-approaches-to-improving-understanding-treatment-and-clinical-management-of-neuroendocrine-prostate-cancer.html
Apr 11, 2020
1
TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/115060-tcf4-induces-enzalutamide-resistance-via-neuroendocrine-differentiation-in-prostate-cancer.html
Apr 11, 2020
2
APCCC 2019: Neuroendocrine Prostate Cancer Spectrum - Diagnosis and Treatment
www.urotoday.com/conference-highlights/apccc-2019/114635-apccc-2019-neuroendocrine-prostate-cancer-spectrum-diagnosis-and-treatment.html
Apr 10, 2020
10
ASCO GU 2020: (NIVOSWITCH) - Switch to Nivolumab with TKI Continuation After 12 Weeks of TKI Induction Therapy in Metastatic Renal Cell Carcinoma
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119336-asco-gu-2020-nivoswitch-switch-to-nivolumab-with-tki-continuation-after-12-weeks-of-tki-induction-therapy-in-metastatic-renal-cell-carcinoma.html
Mar 30, 2020
1
ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma: Neoadjuvant Therapy for Localized RCC
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119343-asco-gu-2020-challenging-clinical-scenarios-in-the-management-of-renal-cell-carcinoma-neoadjuvant-therapy-for-localized-rcc.html
Mar 30, 2020
4
ASCO GU 2020: Overall Survival Results for Durvalumab and Savolitinib in Metastatic Papillary Renal Cancer — CALYPSO trial
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119363-asco-gu-2020-overall-survival-results-for-durvalumab-and-savolitinib-in-metastatic-papillary-renal-cancer-calypso-trial.html
Mar 30, 2020
1
ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma - From the Perspective of a Radiologist
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119359-asco-gu-2020-challenging-clinical-scenarios-in-the-management-of-renal-cell-carcinoma-from-the-perspective-of-a-radiologist.html
Mar 30, 2020
5
ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma - From the Perspective of a Radiologist
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119359-asco-gu-2020-challenging-clinical-scenarios-in-the-management-of-renal-cell-carcinoma-from-the-perspective-of-a-radiologist.html
Mar 30, 2020
4
ASCO GU 2020: Comparing Nivolumab versus Everolimus with >5 years of Follow-up in Patients with Advanced Renal Cell Carcinoma: A Final Analysis of the CheckMate 025 Trial
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119378-asco-gu-2020-comparting-nivolumab-versus-everolimus-with-5-years-of-follow-up-in-patients-with-advanced-renal-cell-carcinoma-a-final-analysis-of-the-checkmate-025-trial.html
Mar 30, 2020
4
ASCO GU 2020: Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119346-asco-gu-2020-cytoreductive-nephrectomy-for-metastatic-renal-cell-carcinoma-treated-with-immune-checkpoint-inhibitors-or-targeted-therapy.html
Mar 28, 2020
8
ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Surgeon’s Perspective
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119418-asco-gu-2020-best-of-journals-renal-cell-carcinoma-the-surgeon-s-perspective.html
Mar 25, 2020
1
5 Data transformation | R for Data Science: Exercise Solutions
jrnold.github.io/r4ds-exercise-solutions/transform.html
Feb 14, 2020
1
R for Data Science Solutions
jrnold.github.io/r4ds-exercise-solutions/data-visualisation.html
Feb 14, 2020
1
Pattern of Metastases in Relation to Characteristics of Primary Tumor and Treatment in Patients with Disseminated Urothelial Carcinoma
www.sciencedirect.com/science/article/pii/S0022534701665625
Nov 29, 2017
1
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
www.sciencedirect.com/science/article/pii/S1470204508703401
Nov 23, 2017
1
红德智库
www.hongdezk.com/index.html
Nov 23, 2017
1
Annotating the law | Hypothes.is
web.hypothes.is/
Nov 23, 2017
11